Insight Into Incretin Mimetics for Type 2 Diabetes
|
|
- Maryann Tyler
- 7 years ago
- Views:
Transcription
1 Insight Into Incretin Mimetics for Type 2 Diabetes A CME/CE Program Sponsored by PRIME
2 Learning Objectives Describe current barriers in targeting physiologic defects causing Type 2 diabetes Compare and contrast the therapeutic potential of incretin hormones with existing diabetes therapies Discuss the impact and potential outcomes of incretin mimetics in managed care
3 Diabetes: 20.8 Million and Climbing Estimated 14.6 million diagnosed million undiagnosed Type 2 diabetes accounts for 90-95% of cases Over 4,100 new cases are diagnosed each day Diagnosed Cases (Millions) Data from the Centers for Disease Control and Prevention. Number of Persons with Diagnosed Diabetes, by Age, United States, Accessed at: on 12/13/05.
4 Etiology of Type 2 Diabetes: Insulin Resistance and Diminished Insulin Secretion Genes Insulin Resistance Lifestyle and Diet Normal β-cell function Abnormal β-cell function Hyperinsulinemia Normoglycemia Felig P, et al. Endocrinology and Metabolism. 3rd ed. McGraw-Hill Inc; Adapted from: Dailey G. Relating Pathophysiology to Glucose Control Relative insulin deficiency Hyperglycemia Type 2 diabetes
5 Economic Impact of Diabetes Total expenditures attributable to diabetes in 2002 = $132 billion Direct medical expenditures = $91.8 billion The largest source of direct medical expenditures is inpatient care, nursing home care, and office visits Indirect medical expenditures = $39.8 billion American Diabetes Association. Diabetes Care. 2003;26(3):
6 Economic Impact of Diabetes Median annual direct costs per patient with diet-controlled Type 2 Diabetes, BMI = 30 kg/m 2, and no end organ complications = $1,700 for white men and $2,100 for white women African-American patients generally incur lower costs, indicating they may receive less care Increase in BMI by 10 kg/m 2, use of prescription antihyperglycemic or antihypertensive drugs, CKD, CVA, or PVD may increase costs by up to 30% Requirement for insulin use or presence of CAD (angina and/or MI) may increase costs by 60-90% Requirement for dialysis increases costs 11-fold Brandle M, et al. Diabetes Care. 2003;26(8):
7 Excess U.S. Health Care Cost Attributable to Diabetes in 2002 Cost of Outpatient Care and Medications $ Millions 12,000 10,000 8,000 6,000 4,000 $10,033 million $3,930 million < or older $5,009 million $6,991 million $5,516 million 2,000 0 Physician Home Visits $146 million Ambulance OAD Insulin Other Medication American Diabetes Association. Diabetes Care. 2003;26: OAD = Oral Antidiabetic Drug
8 DCCT and UKPDS: Rising A1C Associated With Rising Complication Risk Continuous relationship between A1C and complication risk Lower A1C associated with lower complication risk No glycemic threshold down to normal range Rate/100 Patient Years DCCT (Type 1) Retinopathy Incidence/100 Patient Years UKPDS (Type 2) Microvascular A1C (%) A1C (%) DCCT Research Group. Diabetes 1996; 45: Adapted from Stratton IM, et al. BMJ 2000; 321:
9 HbA1C Goals For Clinical Practice > % of MCO population NCQA 2002 HEDIS: poor control HbA1C (%) >8.0 <7.0 < ADA: recommended target AACE/ACE: recommended target Upper limit of normal range 5.5 ADA. Diabetes Care. 2002; 25(s1): S33-S49. ACE Consensus Conference on Guidelines for Glycemic Control. Endocrine Practice 2001 HEDIS Washington: National Committee for Quality Assurance, State of Managed Care Quality. National Committee for Quality Assurance, 2000.
10 Reduction in A1C Reduces Complications A1C Retinopathy Nephropathy DCCT 8.7 vs. 7% 54-76% 34-43% UKPDS 7.9 vs. 7% 21% 34% DCCT Research Group. N Engl J Med.1993; 329: UKPDS Group. Lancet.1998; 352:
11 Cumulative Incidence of New Clinical Albuminuria > 300 mg/24 h During EDIC Cumulative Incidence (%) % risk reduction p < EDIC Year DCCT/EDIC Research Group. JAMA. 2002;287:
12 Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type I Diabetes Cumulative Incidence of Any Predefined Cardiovascular Outcome Conventional Treatment Intensive Treatment No. at Risk: Years Since Entry Intensive treatment Conventional treatment Cumulative Incidence of Nonfatal Myocardial Infarction, Stroke, or Death from Cardiovascular Disease Conventional Treatment Intensive Treatment No. at Risk: Years Since Entry Intensive treatment Conventional treatment Nathan D. et al. New Engl J Med. 2005;353:
13 Lower A1C Values Related to Lower Costs Retrospective database analysis designed to determine whether Type 2 diabetic patients treated in a managed care organization with Hb A1C 7.0% [at target level ] have lower diabetes-related costs than those > 7.0% [above target level ] 46% identified patients at target level with total 1 year costs of $1,171 54% identified patients above target level with total 1 year costs of $1,540, an excess of 32% (p < 0.001) Shetty S, et al. J Manag Care Pharm. 2005;11(7):
14 Targets for Glycemic Control A1C (%) Normal: 4%-6% Fasting or Preprandial (mg/dl) Postprandial (mg/dl) ADA < 7.0% < 180* ACE 6.5% < 110 < 140 *peak postprandial 2-hour postprandial American Diabetes Association. Diabetes Care. 2005;28(suppl 1):S10. American Association of Clinical Endocrinologists. Endocr Pract. 2002;8(Suppl 1):5-11.
15 Currently Available Therapies for Type 2 Diabetes Oral insulin secretagogues Sulfonylureas (e.g., glyburide) Repaglinide Nateglinide Biguanides Thiazolidinediones Alpha-Glucosidase Inhibitors Human insulin and analogues Pramlintide Exenatide
16 Some Limitations of Therapy for Type 2 Diabetes Risk of hypoglycemia Inadequate postprandial glucose control Unpredictable glucose fluctuations Weight gain Progressive β-cell failure Over time, most patients will fail to maintain goal glycemia with oral therapy for Type 2 diabetes because of progressive β-cell failure
17 Novel Therapeutic Approach Restoring the Loss of Incretin Effect in Diabetes
18 Incretin Effect Plasma Insulin Responses to Oral and Intravenous Glucose Normal Weight: Non-Diabetic Subjects Normal Weight: Diabetic Subjects Plasma Insulin (µu/ml) Oral Glucose Intravenous Glucose Plasma Insulin (µu/ml) Oral Glucose Intravenous Glucose Time (min) Non-Diabetic Subjects (glucose range mmol/l) Diabetic Subjects (glucose range mmol/l) Data from: Perley M, et al. J Clin Invest. 1967; 46: Time (min) = The Incretin Effect
19 The Incretin Hormones Peptide hormones secreted by the neuroendocrine cells of the gastrointestinal tract in response to nutrient ingestion Help to modulate pancreatic islet cell secretions Major incretins that affect glucose metabolism: GLP-1: glucagon-like peptide-1 GIP: glucose-dependent insulinotropic polypeptide Drucker DJ. Gastroenterology. 2002;122(2):
20 Glucagon-Like Peptide-1 (GLP-1) Product of the proglucagon gene secreted by intestinal L-cells Released rapidly in response to meals Has a very short half-life in vivo and is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) into inactive metabolites which are renally excreted Patients with impaired glucose tolerance and Type 2 diabetes have lower plasma levels of GLP-1 compared to healthy individuals Toft-Neilsen M, et al. J Clin Endocrinol Metab. 2001;86: Deacon CF, et al. Diabetes 1995;44:
21 Effects of GLP-1 on β-cells Acute: Enhances glucose-dependent insulin secretion Subacute: Stimulates transcription of proinsulin and biosynthesis of insulin Increases expression of Glut-2 and glucokinase Chronic: Stimulates proliferation and neogenesis of β-cells from precursor ductal cells and inhibits β-cell apoptosis Drucker DJ. Mol Endocrinol 2003; 17: Farilla L, et al. Endocrinology 2002;143(11):
22 GLP-1 Modes of Action in Humans Upon ingestion of food Stimulates glucose-dependent insulin secretion Suppresses glucagon secretion GLP-1 is secreted from the L-cells in the intestine Slows gastric emptying Reduces food intake This in turn Drucker DJ. Curr Pharm Des. 2001; 7: Drucker DJ. Mol Endocrinol. 2003; 17: Long term effects demonstrated in animals Increases β-cell mass and maintains β-cell efficiency
23 Enhancing the Effects of GLP-1 in Patients with Type 2 Diabetes Continuous infusion of native GLP-1 May be impractical outside the research setting Extending the activation of GLP-1 receptors Naturally occurring exendin-4 (Heloderma suspectum) Synthetic version = exenatide Long-acting GLP-1 analogues Blocking the degradation of GLP-1 DPP-IV inhibitors
24 Effect of 6-Week Course of GLP-1 Infusion in Type 2 Diabetes GLP-1 as a continuous subcutaneous infusion for 6 weeks resulted in: Lowered fasting plasma glucose by 77 mg/dl and mean plasma glucose by 100 mg/dl Decreased A1C levels by 1.3% Decreased body weight by 2-3 kg Increased insulin sensitivity by 77% Zander M, et al. Lancet. 2000;359:
25 Exendin-4 and GLP-1 Amino Acid Sequences: Exenatide (synthetic exendin-4) has an amino acid sequence that overlaps with native GLP-1 In clinical studies, exenatide exhibited actions that are similar to those of GLP-1: Glucose dependent stimulation of insulin secretion Glucose dependent suppression of postprandial glucagon secretion Slowing of gastric emptying Exenatide was recently approved by the FDA for the treatment of Type 2 Diabetes Eng J, et al. J Biol Chem 1992; 267: ; Keating GM. Drugs 2005;65(12):
26 Effect of Exenatide on Postprandial Glucose and Glucagon in Type 2 Diabetes Placebo Exenatide 0.1 µg/kg Placebo Exenatide 0.1 µg/kg Plasma Glucagon (pg/ml) Exenatide or Placebo Standardized Breakfast Plasma Glucose (mmol/l) Exenatide or Placebo Standardized Breakfast Time (min) Time (min) Data adapted from Kolterman OG, et al. J Clin Endocrinol Metab. 2003; 88:
27 Effect of Exenatide on Fasting Plasma Glucose and Insulin in Type 2 Diabetes Serum Insulin (pmol/l) Placebo 0.05 µg/kg exenatide 0.1 µg/kg exenatide 0.2 µg/kg exenatide Plasma Glucose (mmol/l) Placebo 0.05 µg/kg exenatide 0.1 µg/kg exenatide 0.2 µg/kg exenatide Time (h) Time (h) Data adapted from: Kolterman OG, et al. J Clin Endocrinol Metab. 2003; 88:
28 Effect of 4 Weeks of Exenatide Treatment on A1C in Type 2 Diabetes Patients Mean (SE) Change in AIC (%) Placebo Exanatide (Breafast/Dinner) Exenatide (Breakfast/Bedtime) P < compared to placebo. Exenatide (TID) Fineman MS, et al. Diabetes Care. 2003; 26:
29 Exenatide Large Phase 3 Clinical Studies (ITT) Δ A1C (%) * Baseline * MET 1 n * Placebo BID Exenatide 5 mcg BID Exenatide 10 mcg BID -0.5* SFU 2 MET + SFU 3-0.9* -0.6* * Mean (SE): *P < DeFronzo. Diabetes Care. 2005;28: Buse. Diabetes Care. 2004;27: Kendall. Diabetes Care. 2005;28:1083.
30 Large Exenatide Phase 3 Clinical Studies Patients Achieving A1C 7% (ITT) % Achieving A1C 7% MET (n = 243) 1 * 32 * 46 Placebo BID Exenatide 5 mcg BID Exenatide 10 mcg BID SFU (n = 237) 2 * 33 * 41 MET + SFU (n = 554) 3 * 27 * Evaluable patients at 30 weeks with baseline A1C > 7%; *P < DeFronzo. Diabetes Care. 2005;28: Buse. Diabetes Care. 2004;27: Kendall. Diabetes Care. 2005;28:1083.
31 Weight Changes: Exenatide + Oral Agent Therapy 30-Week, Randomized, Placebo-Controlled Trials Change in Weight (kg) Placebo Exenatide 5 mcg Exenatide 10 mcg * Exenatide + SU 1 (n=377) 1. Buse. Diabetes Care. 2004;27: DeFronzo. Diabetes Care. 2005;28: Kendall. Diabetes Care. 2005;28: * -1.6* -1.6* -2.8* Exenatide + Met 2 (n=336) Exenatide + SU + Met 3 (n=733) *P < 0.05 vs placebo
32 Major Adverse Events Associated with Exenatide Across All Studies Adverse Event Nausea Severe Nausea Hypoglycemia Dizziness Vomiting Diarrhea Headache Placebo 7-23% 2% 3-13% 6-7% 2-5% 4-8% 5-7% Exenatide 36-45% 3-5% 25% 4-15% 11-15% 10-17% 7-11% Buse JB, et al for the Exenatide-113 Clinical Study Group. Diabetes Care. 2004;27: DeFronzo RA, et al. Diabetes Care. 2005;28: Kendall DM, et al. Diabetes Care. 2005;28:
33 Exenatide vs. Glargine Insulin in Patients Failing Oral Agent Therapy Hemoglobin A 1c Level (%) Exenatide group (n = 275) Insuline glargine group (n = 260) Weeks Exenatide Group, n Insulin Glargine Group, n Heine, R J, et al. Ann Intern Med. 2005;143: Change in Body Weight (kg) * * * * Exenatide group (n = 275) Insulin glargine group (n = 260) Weeks Exenatide Group, n Insulin Glargine Group, n *P < * *
34 Liraglutide (NN2211) His Ala Glu Gly Thr Phe Thr Ser Asp Val C-16 fatty acid (palmitoyl) Glu Glu Lys Ala Ala Gln Gly Glu Leu Tyr Ser Ser Phe Ile Ala Trp Leu Val Lys Arg Gly Arg Gly Liraglutide is a long-acting GLP-1 analogue currently in clinical trials* Acylation of GLP-1 improves pharmacokinetics by slowing absorption, reducing renal clearance, and slowing degradation by DPP-IV *Novo Nordisk expects to communicate full results from the phase 2b study at a scientific meeting in Knudsen LB, et al. J Med Chem 2000;43: Available at: Accessed on December 19, 2005.
35 Liraglutide (NN2211) Has a prolonged half-life (11-15 hours) when compared to native GLP-1 In early clinical trials*, has shown the ability to: Increase insulin secretion Suppress post-prandial glucagon secretion Delay gastric emptying Decrease A1C Decrease fasting blood sugar Improved glycemic control without weight gain *Novo Nordisk expects to communicate full results from the phase 2b study at a scientific meeting in Diabetes Care Aug;27(8): Diabet Med Aug;22(8):
36 Effects of Liraglutide on A1C after 12 weeks treatment 0,8 Change A1C (%) vs pbo, mean (95%CI) 0,4 0-0,4-0,8-1,2 Liraglutide mg mg 0.45 mg 0.60 mg 0.75 mg Matthews D, et al. Diabetes. 2002;51(Suppl 2):A84. Glimepiride
37 DPP-IV Inhibitors GLP-1 Secretion and Metabolism Mixed Meal Intestinal GLP-1 Release Plasma GLP-1(7-36) Active GLP-1 Actions DPP-IV XRapid Inactivation (> 80% of Pool) GLP-1(9-36) Inactive Renal Clearance Since DPP-IV rapidly breaks down GLP-1, inhibitors of this enzyme will result in a prolongation in the physiologic actions of GLP-1 Vildagliptin (DPP-IV inhibitor) manufactured by Novartis is currently in phase III trials which are expected to end Available at: Accessed 12/20/05.
38 Effects of the DPP-IV Inhibitor Vildagliptin on Glycemic Control Hemoglobin A1C (%) Studies to date show that DPP-IV inhibitors significantly decrease Hb A1C and other measures of glycemic control. Placebo NVP DPP mg 2 NVP DPP mg Time (weeks) Ahrén B, et al. Diabetes Care. 2002;25:
39 Effects of the DPP-IV Inhibitor Vildagliptin on Glycemic Control Hemoglobin A1C (%) LAF/MET (Core, ITT n = 56) PBOMET (Core, ITT n = 51) LAF/MET (Extension, ITT n = 42) PBO/MET (Extension, ITT n = 29) Time (weeks) Ahrén B, et al. Diabetes Care. 2004;27: Studies to date show that DPP-IV inhibitors significantly decrease Hb A1C and other measures of glycemic control.
40 Current Status of Incretin Related Therapies Exenatide received FDA approval in 2005 as therapy for type 2 patients who have not achieved adequate glycemic control despite treatment with metformin and/or a sulfonylurea agents Both long-acting GLP-1 analogues and oral DPP-IV inhibitors are currently in development
41 Managed Care Issues Cost of medication therapy vs. cost of diabetes and its complications Formulary Status When is prior authorization appropriate Impact of medication tiers and co-pays Medication costs related to other costs including physician and ER visits and hospitalizations Costs and mechanisms of medication acquisition including distribution through specialty pharmacy companies Impact of medication administration: oral vs. injection Need for patient education about disease and treatments Gleeson JM, et al. J Managed Care Pharm. 2005;11(Suppl 7):S2-S13.
42 Conclusions Incretin-related therapies offer great potential for the treatment of people with Type 2 diabetes These therapies have a unique mechanism of action that addresses glucose appearance as well as glucose disappearance As more agents in this class are developed and approved, their appropriate place in the treatment algorithm for Type 2 diabetes will need to be determined
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationSubcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes
Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Mario R. Ehlers, 1,2 Roderick E. Harley, 1 Annette L. Mathisen, 1 Roberta Schneider,
More informationDIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS
Section Two DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS This section will: Describe oral agents (pills) are specific for treating type 2 diabetes. Describe other hypoglycemic agents used
More informationTHE PATHOPHYSIOLOGIC BASIS FOR DIABETES TREATMENT: EVALUATING THE EFFECT OF INCRETIN-BASED THERAPIES * Jack Leahy, MD
THE PATHOPHYSIOLOGIC BASIS FOR DIABETES TREATMENT: EVALUATING THE EFFECT OF INCRETIN-BASED THERAPIES * Jack Leahy, MD ABSTRACT Type 2 diabetes is a persistent public health challenge that requires innovative
More informationStrengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours
Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,
More informationPharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
More informationNew Treatments for Type 2 Diabetes
New Treatments for Type 2 Diabetes Dr David Hopkins Clinical Director, Division of Ambulatory Care King s College Hospital NHS Foundation Trust Treatments for type 2 diabetes - old & new insulin sulphonylureas
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationType 2 Diabetes - Pramlintide and Exenatide
Therapies for Diabetes: Pramlintide and Exenatide MELISSA C. JONES, PharmD, BCPS, South University School of Pharmacy, Savannah, Georgia The American Diabetes Association currently recommends an A1C goal
More informationManagement of Type 2 Diabetes Mellitus in the Elderly
Management of Type 2 Diabetes Mellitus in the Elderly ANDREA FERENCZI, M.D. BANNER ARIZONA MEDICAL CLINIC DEPARTMENT OF ENDOCRINOLOGY Incidence and Prevalence of Diabetes in the United States County-level
More informationAdd: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationWhich drugs should be used to treat diabetes in cirrhotic patients?
Which drugs should be used to treat diabetes in cirrhotic patients? Frankfurt am Main 10-12 September 2015 Jörg Bojunga Medizinische Klinik I Johann Wolfgang Goethe-Universität Frankfurt am Main Significance
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationNew and Future Treatments for Diabetes. Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014
New and Future Treatments for Diabetes Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014 Conflicts of interest Investigator Carmelina study of Linagliptin (Boehringer
More informationType 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action
Aims and Objectives This session will outline the increasing complexities of diabetes care, and the factors that differentiate the combinations of therapy, allowing individualisation of diabetes treatment.
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationVolume 01, No. 08 November 2013
State of New Jersey Department of Human Services Division of Medical Assistance & Health Services New Jersey Drug Utilization Review Board Volume 01, No. 08 November 2013 TO: SUBJECT: PURPOSE: Physicians,
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationClinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus
World Applied Sciences Journal 7 (1): 01-06, 2009 ISSN 1818-4952 IDOSI Publications, 2009 REVIEW ARTICLE Clinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus 1 2 3 1 2 Atif Sitwat
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationInsulin and Other Glucose-Lowering Drugs
Insulin and Other Glucose-Lowering Drugs I. OVERVIEW The pancreas is both an endocrine gland that produces the peptide hormones insulin, glucagon, and somatostatin and an exocrine gland that produces digestive
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationType II diabetes: How to use the new oral medications
Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationStarting Insulin Sooner Than Later
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationInsulin therapy in various type 1 diabetes patients workshop
Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of
More informationNew Non-Insulin Therapies for Type 2 Diabetes Mellitus
New Non-Insulin Therapies for Type 2 Diabetes Mellitus Ally P.H. Prebtani Associate Professor of Medicine Internal Medicine, Endocrinology & Metabolism McMaster University Canada Disclosure Relationships
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationlinagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd
linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationType 2 Diabetes. Jonathon M. Firnhaber, MD. Assistant Professor, Residency Program Director East Carolina University Greenville, North Carolina
Type 2 Diabetes Jonathon M. Firnhaber, MD Assistant Professor, Residency Program Director East Carolina University Greenville, North Carolina Verbal Disclosure It is the policy of the AAFP that all individuals
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationDipeptidyl Peptidase-IV Inhibitors: A New Drug in the Therapeutic Armamentarium for Treatment of Type 2 Diabetes Mellitus
REVIEW ARTICLE JIACM 2009; 10(3): 128-33 Dipeptidyl Peptidase-IV Inhibitors: A New Drug in the Therapeutic Armamentarium for Treatment of Type 2 Diabetes Mellitus Rajesh Rajput* Introduction The incidence
More informationAntidiabetic Drugs. Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Antidiabetic Drugs Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus Two types Type 1 Type 2 Type 1 Diabetes Mellitus Lack of insulin production
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationHow To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
More informationType 2 Diabetes Medicines: What You Need to Know
Type 2 Diabetes Medicines: What You Need to Know Managing diabetes is complex because many hormones and body processes are at work controlling blood sugar (glucose). Medicines for diabetes include oral
More informationClinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives
What s New in Diabetes Medications? Matthew Kostoff, PharmD, BCPS, BCACP Clinical Assistant Professor Clinical Pharmacy Specialist Wesley Family Medicine Residency Program Objectives Discuss new literature
More informationThe epidemic of type 2 diabetes and
Reviews/Commentaries/ADA Statements C O N S E N S U S S T A T E M E N T Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus
More informationInpatient Treatment of Diabetes
Inpatient Treatment of Diabetes Alan J. Conrad, MD Medical Director Diabetes Services EVP, Physician Alignment Diabetes Symposium November 12, 2015 Objectives Explain Palomar Health goals for inpatient
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More informationDiabetes may be classified as. i) Type - I Diabetes mellitus. Type - II Diabetes mellitus. Type - 1.5 Diabetes mellitus. Gestational Diabetes INSULIN
HYPOGLYCEMIC AGENT Diabetes mellitus is a chronic metabolic disorder of multiple aetiology characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting
More informationNoninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause MED GROUP DESCRIPTOR INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) MICRONIZED GLYBURIDE*
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationOverview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice
clinical features Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice Nancy Bohannon, MD 1 1 Monteagle Medical Center, San Francisco, CA Correspondence: Nancy Bohannon,
More informationManaging Patients Newly Diagnosed with Diabetes. Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON
Managing Patients Newly Diagnosed with Diabetes Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON 1 Conflict Disclosure Information Conflict Disclosure Information
More informationAntihyperglycemic Agents Comparison Chart
Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion
More informationEffective pharmacological treatment regimens for diabetes usually require
Medications Used in Diabetes in Patients Presenting for Anesthesia By Gabrielle O Connor, M.D., M.Sc., CCD, MRCP, FACP Dr. Gabrielle O Connor, a board certified endocrinologist who graduated from University
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More information10/30/2012. Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University of South Alabama Mobile, Alabama
Faculty Medications for Diabetes Satellite Conference and Live Webcast Wednesday, November 7, 2012 2:00 4:00 p.m. Central Time Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University
More informationPrimary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD
Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We
More informationPANCREATIC HORMONES, ANTIDIABETIC AGENTS: INSULIN AND ORAL ANTIDIABETICS- handout Iwona Zaporowska-Stachowiak
PANCREATIC HORMONES, ANTIDIABETIC AGENTS: INSULIN AND ORAL ANTIDIABETICS- handout Iwona Zaporowska-Stachowiak The endocrine pancreas (the islets of Langerhans) consists of four types of endocrine cells:
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationMedicines for Type 2 Diabetes A Review of the Research for Adults
Medicines for Type 2 Diabetes A Review of the Research for Adults Is This Information Right for Me? Yes, if: Your doctor or health care provider has told you that you have type 2 diabetes and have high
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationNew Treatment Considerations for Type 2 Diabetes Mellitus
New Treatment Considerations for Type 2 Diabetes Mellitus Release Date: 11/21/2011 Expiration Date: 11/21/2014 FACULTY: Nicole Van Hoey, PharmD FACULTY AND ACCREDITOR DISCLOSURE STATEMENTS: Nicole Van
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationEfficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus
Clin Pediatr Endocrinol 2002; 11(2), 87-92 Copyright 2002 by The Japanese Society for Pediatric Endocrinology Original Efficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus Toshikazu
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationDRUGS FOR GLUCOSE MANAGEMENT AND DIABETES
Page 1 DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Drugs to know are: Actrapid HM Humulin R, L, U Penmix SUNALI MEHTA The three principal hormones produced by the pancreas are: Insulin: nutrient metabolism:
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationNewer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013
Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationFaculty. Program Objectives. Introducing the Problem. Diabetes is a Silent Killer. Minorities at Greater Risk of Having Type 2 Diabetes
Diabetes: The Basics Understanding and Managing Diabetes (Part 1 of 3) Satellite Conference Tuesday, October 18, 2005 2:00-4:00 p.m. (Central Time) Produced by the Alabama Department of Public Health Video
More informationTreating Type 2 Diabetes Mellitus: a New York State Medicaid Clinical Guidance Document
Treating Type 2 Diabetes Mellitus: a New York State Medicaid Clinical Guidance Document Disclaimer: This document is offered as a service to New York State Prescribers to inform about the most current
More informationHow To Get Better Health Care
Kardiovaskulär säkerhet vid behandling av typ 2-diabetes Vad säger senaste data? Michael Alvarsson Kliniken för Endokrinologi, Metabolism och Diabetes Karolinska Universitetssjukhuset Solna Near-normal
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More informationDefinition of Diabetes Mellitus
Definition of Diabetes Mellitus Diabetes mellitus consists of a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. U.S. Diabetes
More informationType 2 diabetes mellitus current therapies and the emergence of surgical options
Type 2 diabetes mellitus current therapies and the emergence of surgical options Harold E. Lebovitz Abstract Patients with type 2 diabetes mellitus (T2DM) are usually treated with pharmacologic agents
More information